Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

DA Davidson lowered the firm’s price target on Vertex (VERX) to $50 from $55 and keeps a Buy rating on the shares as part of a broader research ...

Vertex (VERX) announced the expansion of its Chief Strategy Office with the addition of Christopher Hall and Kathya Capote Peimbert. Their ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

BOSTON, April 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner ...

Vertex Inc. (NASDAQ: VERX) has expanded its Chief Strategy Office with the addition of Christopher Hall and Kathya Capote ...

Zacks Research has upped the financial bar for Vertex Pharmaceuticals, boosting its 2026 earnings forecast from $16.18 to $16 ...